171 related articles for article (PubMed ID: 1649576)
41. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides.
Perno CF; Yarchoan R; Cooney DA; Hartman NR; Gartner S; Popovic M; Hao Z; Gerrard TL; Wilson YA; Johns DG
J Exp Med; 1988 Sep; 168(3):1111-25. PubMed ID: 2844951
[TBL] [Abstract][Full Text] [Related]
42. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients.
Mohri H; Singh MK; Ching WT; Ho DD
Proc Natl Acad Sci U S A; 1993 Jan; 90(1):25-9. PubMed ID: 7678340
[TBL] [Abstract][Full Text] [Related]
43. Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates.
Gong YF; Marshall DR; Srinivas RV; Fridland A
Antimicrob Agents Chemother; 1994 Jul; 38(7):1683-7. PubMed ID: 7979311
[TBL] [Abstract][Full Text] [Related]
44. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1.
Salomon H; Belmonte A; Nguyen K; Gu Z; Gelfand M; Wainberg MA
J Clin Microbiol; 1994 Aug; 32(8):2000-2. PubMed ID: 7527427
[TBL] [Abstract][Full Text] [Related]
45. Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds.
Wondimu Z; Sönnerborg A; Ayehunie S; Britton S; Strannegård O
Antiviral Res; 1992 Oct; 19(4):353-9. PubMed ID: 1281393
[TBL] [Abstract][Full Text] [Related]
46. New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3'-azido-3'-deoxythymidine: inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens.
Schwendener RA; Gowland P; Horber DH; Zahner R; Schertler A; Schott H
Antiviral Res; 1994 May; 24(1):79-93. PubMed ID: 7944315
[TBL] [Abstract][Full Text] [Related]
47. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
48. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.
Schinazi RF; McMillan A; Cannon D; Mathis R; Lloyd RM; Peck A; Sommadossi JP; St Clair M; Wilson J; Furman PA
Antimicrob Agents Chemother; 1992 Nov; 36(11):2423-31. PubMed ID: 1283296
[TBL] [Abstract][Full Text] [Related]
49. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
Gao WY; Johns DG; Tanaka M; Mitsuya H
Mol Pharmacol; 1999 Mar; 55(3):535-40. PubMed ID: 10051538
[TBL] [Abstract][Full Text] [Related]
50. [Replicative properties of HIV-1 strains, resistant to 3'-azido-2'3'-dideoxythymidine].
Selimova LM; Iurin OG; Pokrovskiĭ VV
Vopr Virusol; 1997; 42(1):10-3. PubMed ID: 9103035
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of 3'azido-3'deoxythymidine-resistant HIV-1 infection by dehydroepiandrosterone in vitro.
Yang JY; Schwartz A; Henderson EE
Biochem Biophys Res Commun; 1994 Jun; 201(3):1424-32. PubMed ID: 8024587
[TBL] [Abstract][Full Text] [Related]
52. Long-term persistence of AZT-resistance mutations in the plasma HIV-1 of patients removed from AZT therapy.
Smith MS; Koerber KL; Pagano JS
Leukemia; 1994 Apr; 8 Suppl 1():S179-82. PubMed ID: 8152287
[TBL] [Abstract][Full Text] [Related]
53. In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol.
St Clair MH; Pennington KN; Rooney J; Barry DW
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S83-91. PubMed ID: 7552518
[TBL] [Abstract][Full Text] [Related]
54. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro.
Johnson VA; Merrill DP; Chou TC; Hirsch MS
J Infect Dis; 1992 Nov; 166(5):1143-6. PubMed ID: 1328402
[TBL] [Abstract][Full Text] [Related]
55. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus.
Richman DD; Meng TC; Spector SA; Fischl MA; Resnick L; Lai S
J Acquir Immune Defic Syndr (1988); 1994 Feb; 7(2):135-8. PubMed ID: 7905522
[TBL] [Abstract][Full Text] [Related]
56. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
Bazmi HZ; Hammond JL; Cavalcanti SC; Chu CK; Schinazi RF; Mellors JW
Antimicrob Agents Chemother; 2000 Jul; 44(7):1783-8. PubMed ID: 10858331
[TBL] [Abstract][Full Text] [Related]
57. Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC.
Gu Z; Gao Q; Faust EA; Wainberg MA
J Gen Virol; 1995 Oct; 76 ( Pt 10)():2601-5. PubMed ID: 7595365
[TBL] [Abstract][Full Text] [Related]
58. Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine.
Remington KM; Chesebro B; Wehrly K; Pedersen NC; North TW
J Virol; 1991 Jan; 65(1):308-12. PubMed ID: 1845891
[TBL] [Abstract][Full Text] [Related]
59. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
[TBL] [Abstract][Full Text] [Related]
60. Targeted therapy of human immunodeficiency virus-related disease.
Mitsuya H; Yarchoan R; Kageyama S; Broder S
FASEB J; 1991 Jul; 5(10):2369-81. PubMed ID: 1712326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
